MedTrace Logo

N-acetylcysteine for Renal Protection in Patients With Rheumatic Heart Disease Undergoing Valve Replacement

NCT01704482 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2012-10-11

No results posted yet for this study

Summary

We aim to investigate the efficacy of N-acetylcysteine (NAC) to attenuate acute renal dysfunction in patients with rheumatic valvular heart disease undergoing single valve replacement.

Conditions

  • Cardiac Surgery for Rheumatic Valvular Heart Disease
  • Renal Dysfunction

Interventions

DRUG

N-acetylcysteine

NAC bolus of 150 mg/kg in 250 mL of 5% glucose over 15 mins, followed by continuous intravenous infusion of 50 mg/kg in 250 mL of 5% glucose over 4 hrs, then 100 mg/kg in 1000 ml of 5% glucose over 20 hrs

DRUG

placebo

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Principal Investigators

  • Laila H Mohamed, Prof · Assiut university hosiptal

  • Nawal A Gad El-rab, Prof · Assiut university hosiptal

  • Fatma A Abd El-Aal, Ass Prof · Assiut university hosiptal

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-02-28
Primary Completion
2012-09-30
Completion
2012-09-30

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01704482 on ClinicalTrials.gov